Generics
Perrigo passes US FDA's tentative approval for generic onexton acne vulgaris gel
29 January 2018 -

Healthcare company Perrigo Company plc (NYSE:PRGO)(TASE:PRGO) reported on Friday the receipt of tentative approval from the US Food and Drug Administration for the generic version of Onexton Gel (clindamycin phosphate 1.2% and benzoyl peroxide 3.75%) for the treatment of acne vulgaris.

According to the company, Onexton Gel (clindamycin phosphate 1.2% and benzoyl peroxide 3.75%) is a prescription medicine indicated for the topical treatment of acne vulgaris in patients 12 years of age and older.

For the last 12 months, branded market sales were approximately USD115m, added the company.

In conjunction, the company said it had previously settled litigation with Valeant Pharmaceuticals North America LLC and Dow Pharmaceutical Sciences Inc for Onexton Gel (clindamycin phosphate 1.2% and benzoyl peroxide 3.75%).

Login
Username:

Password: